{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "31",
                    "patients_percentage": "44"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[7.6, 12.7]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "31",
                    "patients percentage": "44%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[7.6, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "31",
                    "patients_percentage": "44"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[7.6, 12.7]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "31",
                    "patients percentage": "44%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[12.7, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "31",
                    "patients_percentage": "44"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[7.6, 12.7]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "6",
                    "patients percentage": "8%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[2.8, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "31",
                    "patients_percentage": "44"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[7.6, 12.7]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "6",
                    "patients percentage": "8%",
                    "PFS (months)": "2.8",
                    "OS (months)": "5.9",
                    "PFS p-value": "0.05",
                    "OS p-value": "0.0012",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[5.9, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "31",
                    "patients_percentage": "44"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[7.6, 12.7]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "27",
                    "patients percentage": "38%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[3.3, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "31",
                    "patients_percentage": "44"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[7.6, 12.7]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "27",
                    "patients percentage": "38%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[8.6, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "31",
                    "patients_percentage": "44"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[7.6, 12.7]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "7",
                    "patients percentage": "10%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[2.2, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "31",
                    "patients_percentage": "44"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[7.6, 12.7]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "7",
                    "patients percentage": "10%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[5.2, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "6",
                    "patients_percentage": "8"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.8, 5.9]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "31",
                    "patients percentage": "44%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[7.6, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "6",
                    "patients_percentage": "8"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.8, 5.9]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "31",
                    "patients percentage": "44%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[12.7, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "6",
                    "patients_percentage": "8"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.8, 5.9]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "6",
                    "patients percentage": "8%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[2.8, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "6",
                    "patients_percentage": "8"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.8, 5.9]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "6",
                    "patients percentage": "8%",
                    "PFS (months)": "2.8",
                    "OS (months)": "5.9",
                    "PFS p-value": "0.05",
                    "OS p-value": "0.0012",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[5.9, 0.0012]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "27",
                    "patients_percentage": "38"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[3.3, 8.6]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "31",
                    "patients percentage": "44%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[7.6, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "27",
                    "patients_percentage": "38"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[3.3, 8.6]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "31",
                    "patients percentage": "44%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[12.7, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "27",
                    "patients_percentage": "38"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[3.3, 8.6]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "6",
                    "patients percentage": "8%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[2.8, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "27",
                    "patients_percentage": "38"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[3.3, 8.6]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "27",
                    "patients percentage": "38%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[3.3, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "27",
                    "patients_percentage": "38"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[3.3, 8.6]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "27",
                    "patients percentage": "38%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[8.6, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "27",
                    "patients_percentage": "38"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[3.3, 8.6]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "7",
                    "patients percentage": "10%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[2.2, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH \u2264 UNR",
                    "patients_number": "27",
                    "patients_percentage": "38"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[3.3, 8.6]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "7",
                    "patients percentage": "10%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[5.2, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "7",
                    "patients_percentage": "10"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.2, 5.2]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "31",
                    "patients percentage": "44%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[7.6, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "7",
                    "patients_percentage": "10"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.2, 5.2]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "31",
                    "patients percentage": "44%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[12.7, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "7",
                    "patients_percentage": "10"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.2, 5.2]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "6",
                    "patients percentage": "8%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[2.8, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "7",
                    "patients_percentage": "10"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.2, 5.2]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "27",
                    "patients percentage": "38%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[3.3, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "7",
                    "patients_percentage": "10"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.2, 5.2]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "27",
                    "patients percentage": "38%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[8.6, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "7",
                    "patients_percentage": "10"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.2, 5.2]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "7",
                    "patients percentage": "10%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[2.2, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "population_subgroup": "No Sorafenib group",
                    "ldh_level": "LDH > UNR",
                    "patients_number": "7",
                    "patients_percentage": "10"
                },
                "measures": "[PFS, OS]",
                "outcomes": "[2.2, 5.2]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "7",
                    "patients percentage": "10%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[5.2, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study_name": "MAPS",
                    "study_phase": "II",
                    "treatment_comparison": "chemotherapy plus sorafenib vs chemotherapy alone"
                },
                "measures": "[PFS p-value, OS p-value]",
                "outcomes": "[0.05, 0.0012]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "31",
                    "patients percentage": "44%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[7.6, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study_name": "MAPS",
                    "study_phase": "II",
                    "treatment_comparison": "chemotherapy plus sorafenib vs chemotherapy alone"
                },
                "measures": "[PFS p-value, OS p-value]",
                "outcomes": "[0.05, 0.0012]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "31",
                    "patients percentage": "44%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[12.7, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study_name": "MAPS",
                    "study_phase": "II",
                    "treatment_comparison": "chemotherapy plus sorafenib vs chemotherapy alone"
                },
                "measures": "[PFS p-value, OS p-value]",
                "outcomes": "[0.05, 0.0012]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy plus sorafenib",
                    "patients number": "6",
                    "patients percentage": "8%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[2.8, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study_name": "MAPS",
                    "study_phase": "II",
                    "treatment_comparison": "chemotherapy plus sorafenib vs chemotherapy alone"
                },
                "measures": "[PFS p-value, OS p-value]",
                "outcomes": "[0.05, 0.0012]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "27",
                    "patients percentage": "38%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[3.3, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study_name": "MAPS",
                    "study_phase": "II",
                    "treatment_comparison": "chemotherapy plus sorafenib vs chemotherapy alone"
                },
                "measures": "[PFS p-value, OS p-value]",
                "outcomes": "[0.05, 0.0012]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH \u2264 UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "27",
                    "patients percentage": "38%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[8.6, 0.0012]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study_name": "MAPS",
                    "study_phase": "II",
                    "treatment_comparison": "chemotherapy plus sorafenib vs chemotherapy alone"
                },
                "measures": "[PFS p-value, OS p-value]",
                "outcomes": "[0.05, 0.0012]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "7",
                    "patients percentage": "10%",
                    "unit": "months"
                },
                "measures": "[PFS, p]",
                "outcomes": "[2.2, 0.05]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study_name": "MAPS",
                    "study_phase": "II",
                    "treatment_comparison": "chemotherapy plus sorafenib vs chemotherapy alone"
                },
                "measures": "[PFS p-value, OS p-value]",
                "outcomes": "[0.05, 0.0012]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "study": "MAPS phase II",
                    "analysis": "PFS and OS",
                    "population subgroup": "No Sorafenib group",
                    "LDH level": "LDH > UNR",
                    "treatment": "chemotherapy alone",
                    "patients number": "7",
                    "patients percentage": "10%",
                    "unit": "months"
                },
                "measures": "[OS, p]",
                "outcomes": "[5.2, 0.0012]"
            },
            "match": "no"
        }
    ],
    "total_extracted_claims": 5,
    "total_ground_truth_claims": 8,
    "number_of_matches": 1
}